The Human Biome was established as a Medical University of Warsaw spin-off due to the commercialization of our scientific research. Initially at the University, then at the Human Biome, in close cooperation with academia, since 2014, we conduct research on the gut microbiome as a new type of biotherapeutic agent. Having very rich baggage of experience in hematology, transplantation, immunology, and microbiology, we have combined many fields of medicine and technology to enter the world of the microbiome and discover what is undiscovered.
HBI combines highly innovative microbiome knowledge and breakthrough technologies in one unique approach that is able to generate a pipeline of donor-independent New Generation Biotherapeutics (NGBs) as a Live Biotherapeutics Products (LBPs).
Technologies and microbiome products developed by HBI:
1. “MicroDrug®” - AI/ML-based in-silico and ultra-deep tech in-vitro lab composing Drug Discovery Platform to predict microbiota-based drugs:
- "Trapp MIcroBS" - in-silico computational platform predicting drug compositions
- “Q Lab” - highly innovative in-vitro laboratory applying microfluidic, genomic, culturomic and robotic technologies to synthesize New Generation Biotherapeutics.
2. Microbiome Biobank - over 20 000 samples collected to date, from unique donors and patients (triads) treated by in-house produced highly rich and viable microbiota transplant preparations (Mbiotix)
3. Fecal Microbiota Transplantation (FMT) Facility with Clinical Platform (HBI leads 8 clinical experiments based on FMT to discover context-oriented drug compositions)
4. “Mbiotix” - highest-quality FMT preparation delivered to over 1400 patients.
Currently, in the HBI pipeline are developed 4 New-Generation Biotherapeutics (NGB):
- anti-CDI NGB (anti Clostridioides difficile NGB)
- flagship anti-ARB/AI NGB (anti-antibiotic resistant bacteria and anti-infective NGB)
- immunobooster NGB (GvHD and immunooncology)
- longevity/wellbeing NGB.
